Company: NPO
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001140361-25-014736
Chunk: 0

Company: Enpro Inc.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under §240.14a-12 |

Enpro Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-(6)(i)(1) and 0-11 |

| Enpro Inc.                      
 5605 Carnegie Boulevard,        
 Suite 500                       
 Charlotte, North Carolina 28209 |

ENPRO INC. SUPPLEMENTAL PROXY MATERIAL For the 2025 Annual Meeting of Shareholders to be Held on April 30, 2025 April 21, 2025 Supplemental Biographical Information This information supplements the definitive proxy statement (the “Proxy Statement”) filed by Enpro Inc. (the “Company”) on March 24, 2025 relating to the Company’s 2025 Annual Meeting of Shareholders to be held on April 30, 2025 (the “Annual Meeting”), as supplemented by the supplemental proxy material filed by the Company on March 25, 2025 (the “March Supplement”). The Company is providing this supplemental information solely to update the biography of Adele M. Gulfo. Ms. Gulfo is a current director standing for re-election to the Company’s Board of Directors at the Annual Meeting. On April 17, 2025, the board of directors of NewAmsterdam Pharma Company N.V. (“NewAmsterdam”), a public company, elected Ms. Gulfo to serve as a director of NewAmsterdam